The global anti-Parkinson’s drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1% from 2017 to 2022.
Report Includes
95 data tables
Country specific data and analysis for China, India, Japan, Australia, United Kingdom, Germany, France, Italy, Spain, Russia, USA, and Brazil
Analyses of the major factors and technological advances such as biomarkers, 3D printed drugs, mobile applications and wearable technologies in the monitoring and treatment of Parkinson’s disease
Discussion of the major segments of the anti-Parkinson’s drugs, i.e., dopaminergic drugs, dopamine agonists, enzyme inhibitors and other anti-Parkinson’s medications
Company profiles of the major players in the market, including AbbVie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis
Report Scope
This research report categorizes the anti-Parkinson’s drugs market by type. Product types include low dopaminergic, dopamine agonists, enzyme inhibitors and other anti-Parkinson’s medications.
Analyst Credentials
BCC Research analysts craft reference reports with a unique end noted referencing methodology, which allows users to cross reference and trace market numbers back to their source. These individuals are experts in secondary research and primary forecasting - compiling and layering existing data with their original research and analysis. The team has decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies
The global market for protein expression should grow from $1.8 billion in 2017 to $3.1 billion by 2022 at a compound annual growth rate (CAGR) of 11.3% from 2017 through 2022.
The global cognition and memory-enhancing drugs market should reach over $4.2 billion by 2022 from $2.8 billion in 2017 at a compound annual growth rate (CAGR) of 8.7% for the period 2017-2022.
The global market for neuroprotective agents will grow from $54.4 billion in 2017 to $75.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.8% for the period of 2017-2022.
The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022.
Shalini Shahani Dewan | Jan 2018
Share This Report
Custom Research - PHM193A
Download Report Overview - Anti-Parkinson's Drugs: Global Markets to 2022
Complete the form below and we'll send you a private, secure link to download the Report Sample as a PDF.
